| Year |
Citation |
Score |
| 2023 |
Staedtke V, Anstett K, Bedwell D, Giovannini M, Keeling K, Kesterson R, Kim Y, Korf B, Leier A, McManus ML, Sarnoff H, Vitte J, Walker JA, Plotkin SR, Wallis D. Gene-targeted therapy for neurofibromatosis and schwannomatosis: The path to clinical trials. Clinical Trials (London, England). 17407745231207970. PMID 37937606 DOI: 10.1177/17407745231207970 |
0.549 |
|
| 2023 |
Chiasson-MacKenzie C, Vitte J, Liu CH, Wright EA, Flynn EA, Stott SL, Giovannini M, McClatchey AI. Cellular mechanisms of heterogeneity in NF2-mutant schwannoma. Nature Communications. 14: 1559. PMID 36944680 DOI: 10.1038/s41467-023-37226-0 |
0.638 |
|
| 2019 |
Roberts DS, Maurya R, Takemon Y, Vitte J, Gong L, Zhao J, Wong CH, Slattery W, Peng KA, Lekovic G, Schwartz MS, Bulsara K, Ngan CY, Giovannini M, Wei CL. Linked-read Sequencing Analysis Reveals Tumor-specific Genome Variation Landscapes in Neurofibromatosis Type 2 (NF2) Patients. Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology. 40: e150-e159. PMID 30624408 DOI: 10.1097/Mao.0000000000002096 |
0.639 |
|
| 2019 |
Fuse MA, Dinh CT, Vitte J, Kirkpatrick J, Mindos T, Plati SK, Young JI, Huang J, Carlstedt A, Franco MC, Brnjos K, Nagamoto J, Petrilli A, Copik AJ, Soulakova JN, et al. Preclinical Assessment of MEK1/2 Inhibitors for Neurofibromatosis Type 2-Associated Schwannomas Reveal Differences in Efficacy and Drug Resistance Development. Neuro-Oncology. PMID 30615146 DOI: 10.1093/Neuonc/Noz002 |
0.641 |
|
| 2019 |
Osum S, Stemmer-Rachamimov A, Widemann B, Dombi E, Vitte J, Dahiya S, Rizvi T, Ratner N, Messiaen L, Gutmann D, Giovannini M, Moertel C, Largaespada D, Watson A. TMOD-23. PRECLINICAL DRUG EVALUATION IN A GENETICALLY ENGINEERED MINIPIG MODEL OF NEUROFIBROMATOSIS TYPE 1 Neuro-Oncology. 21: vi267-vi267. DOI: 10.1093/Neuonc/Noz175.1122 |
0.622 |
|
| 2019 |
Vitte J, Gao F, Coppola G, Judkins AR, Giovannini M. TMOD-15. SPATIOTEMPORAL LOSS OF SMARCB1 IN EARLY NEURAL CREST LINEAGE LEADS TO DIFFERENT MOLECULAR SUBTYPES OF RHABDOID TUMORS Neuro-Oncology. 21: ii124-ii124. DOI: 10.1093/Neuonc/Noz036.252 |
0.601 |
|
| 2018 |
Isakson SH, Rizzardi AE, Coutts AW, Carlson DF, Kirstein MN, Fisher J, Vitte J, Williams KB, Pluhar GE, Dahiya S, Widemann BC, Dombi E, Rizvi T, Ratner N, Messiaen L, et al. Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1. Communications Biology. 1: 158. PMID 30302402 DOI: 10.1038/s42003-018-0163-y |
0.566 |
|
| 2017 |
Paganini I, Capone GL, Vitte J, Sestini R, Putignano AL, Giovannini M, Papi L. Double somatic SMARCB1 and NF2 mutations in sporadic spinal schwannoma. Journal of Neuro-Oncology. PMID 29230670 DOI: 10.1007/S11060-017-2711-6 |
0.626 |
|
| 2017 |
Vitte J, Gao F, Coppola G, Judkins AR, Giovannini M. Timing of Smarcb1 and Nf2 inactivation determines schwannoma versus rhabdoid tumor development. Nature Communications. 8: 300. PMID 28824165 DOI: 10.1038/S41467-017-00346-5 |
0.679 |
|
| 2016 |
Shi Y, Bollam SR, White SM, Laughlin SZ, Graham GT, Wadhwa M, Chen H, Nguyen C, Vitte J, Giovannini M, Toretsky J, Yi C. Rac1-Mediated DNA Damage and Inflammation Promote Nf2 Tumorigenesis but Also Limit Cell-Cycle Progression. Developmental Cell. PMID 27818180 DOI: 10.1016/J.Devcel.2016.09.027 |
0.64 |
|
| 2016 |
Bonne NX, Vitte J, Chareyre F, Karapetyan G, Khankaldyyan V, Tanaka K, Moats RA, Giovannini M. An allograft mouse model for the study of hearing loss secondary to vestibular schwannoma growth. Journal of Neuro-Oncology. PMID 27177628 DOI: 10.1007/S11060-016-2150-9 |
0.578 |
|
| 2015 |
Paganini I, Chang VY, Capone GL, Vitte J, Benelli M, Barbetti L, Sestini R, Trevisson E, Hulsebos TJ, Giovannini M, Nelson SF, Papi L. Expanding the mutational spectrum of LZTR1 in schwannomatosis. European Journal of Human Genetics : Ejhg. 23: 963-8. PMID 25335493 DOI: 10.1038/Ejhg.2014.220 |
0.655 |
|
| 2015 |
Vitte J, Chareyre F, Stemmer-Rachamimov A, Judkins A, Giovannini M. PM-02 * CONDITIONAL INACTIVATION OF SMARCB1 IN P0 PERMISSIVE MOUSE CELLS GENERATES RHABDOID TUMORS IN THE PERIPHERAL NERVOUS SYSTEM AND IN THE BRAIN Neuro-Oncology. 17: iii31-iii31. DOI: 10.1093/Neuonc/Nov061.125 |
0.646 |
|
| 2014 |
Giovannini M, Bonne NX, Vitte J, Chareyre F, Tanaka K, Adams R, Fisher LM, Valeyrie-Allanore L, Wolkenstein P, Goutagny S, Kalamarides M. mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma. Neuro-Oncology. 16: 493-504. PMID 24414536 DOI: 10.1093/Neuonc/Not242 |
0.656 |
|
| 2014 |
Vitte J, Chareyre F, Stemmer-Rachamimov A, Judkins A, Giovannini M. Conditional Inactivation of SMARCB1 in P0 Permissive Mouse Cells Generates Rhabdoid Tumors in the Peripheral Nervous System Cancer Genetics. 207: 451. DOI: 10.1016/J.Cancergen.2014.09.023 |
0.592 |
|
| 2013 |
Tanaka K, Eskin A, Chareyre F, Jessen WJ, Manent J, Niwa-Kawakita M, Chen R, White CH, Vitte J, Jaffer ZM, Nelson SF, Rubenstein AE, Giovannini M. Therapeutic potential of HSP90 inhibition for neurofibromatosis type 2. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 3856-70. PMID 23714726 DOI: 10.1158/1078-0432.Ccr-12-3167 |
0.553 |
|
| 2013 |
Plotkin SR, Blakeley JO, Evans DG, Hanemann CO, Hulsebos TJ, Hunter-Schaedle K, Kalpana GV, Korf B, Messiaen L, Papi L, Ratner N, Sherman LS, Smith MJ, Stemmer-Rachamimov AO, Vitte J, et al. Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria. American Journal of Medical Genetics. Part A. 161: 405-16. PMID 23401320 DOI: 10.1002/Ajmg.A.35760 |
0.651 |
|
| 2010 |
Vitte J, Traver S, Maués De Paula A, Lesage S, Rovelli G, Corti O, Duyckaerts C, Brice A. Leucine-rich repeat kinase 2 is associated with the endoplasmic reticulum in dopaminergic neurons and accumulates in the core of Lewy bodies in Parkinson disease. Journal of Neuropathology and Experimental Neurology. 69: 959-72. PMID 20720502 DOI: 10.1097/Nen.0B013E3181Efc01C |
0.449 |
|
| 2009 |
Vitte J, Attali R, Warwar N, Gurt I, Melki J. Spinal muscular atrophy. Advances in Experimental Medicine and Biology. 652: 237-46. PMID 20225030 DOI: 10.1007/978-90-481-2813-6_16 |
0.618 |
|
| 2009 |
Fournier M, Vitte J, Garrigue J, Langui D, Dullin JP, Saurini F, Hanoun N, Perez-Diaz F, Cornilleau F, Joubert C, Ardila-Osorio H, Traver S, Duchateau R, Goujet-Zalc C, Paleologou K, et al. Parkin deficiency delays motor decline and disease manifestation in a mouse model of synucleinopathy. Plos One. 4: e6629. PMID 19680561 DOI: 10.1371/Journal.Pone.0006629 |
0.432 |
|
| 2007 |
Vitte J, Fassier C, Tiziano FD, Dalard C, Soave S, Roblot N, Brahe C, Saugier-Veber P, Bonnefont JP, Melki J. Refined characterization of the expression and stability of the SMN gene products. The American Journal of Pathology. 171: 1269-80. PMID 17717146 DOI: 10.2353/Ajpath.2007.070399 |
0.586 |
|
| 2006 |
Tarrade A, Fassier C, Courageot S, Charvin D, Vitte J, Peris L, Thorel A, Mouisel E, Fonknechten N, Roblot N, Seilhean D, Diérich A, Hauw JJ, Melki J. A mutation of spastin is responsible for swellings and impairment of transport in a region of axon characterized by changes in microtubule composition. Human Molecular Genetics. 15: 3544-58. PMID 17101632 DOI: 10.1093/Hmg/Ddl431 |
0.566 |
|
| 2004 |
Vitte JM, Davoult B, Roblot N, Mayer M, Joshi V, Courageot S, Tronche F, Vadrot J, Moreau MH, Kemeny F, Melki J. Deletion of murine Smn exon 7 directed to liver leads to severe defect of liver development associated with iron overload. The American Journal of Pathology. 165: 1731-41. PMID 15509541 DOI: 10.1016/S0002-9440(10)63428-1 |
0.573 |
|
| Show low-probability matches. |